Phase II trial of pyrazoloacridine in children with solid tumors: A pediatric oncology group Phase II study

American Journal of Pediatric Hematology/Oncology

Volumn 22, Issue 6, 2000, Pages 506-509

  Berg, Stacey L ^a,e   Blaney, Susan M ^a   Sullivan, James ^a   Bernstein, Mark ^b   Dubowy, Ronald ^c   Harris, Michael B ^d  

^a UNIVERSITY OF FLORIDA   (United States)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^d HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^e C/o Pediatric Oncology Group ^*  (United States)

Author keywords

Cancer; Children; Global stopping criterion; Phase II trial; Pyrazoloacridine; PZA

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; ACRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; PYRAZOLE DERIVATIVE;

ADOLESCENT; ADULT; ANXIETY; ARTICLE; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; HUMAN; INFANT; MULTICENTER STUDY; NEOPLASM; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; THROMBOCYTOPENIA;

ACRIDINES; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ANXIETY; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; NEOPLASMS; PATIENT SELECTION; PYRAZOLES; THROMBOCYTOPENIA;

EID: 0034323932     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200011000-00006     Document Type: Article

References (13)

1. Capps D, Ross-Kesten S, Shillis J, et al. 2-aminoalkyl-5-nitropyrazolo[3,4,5-kl]acridines: A new class of anticancer agents. Proc Am Assoc Cancer Res 1986; 27: 277.
2. Scavone S, Sebolt J, Pinter C, et al. Biological and biochemical properties of the 2-aminoalkyl-5-nitropyrazolo[3,4,5-kl]acridines (pyrozoloacridines). Proc Am Assoc Cancer Res 1986; 27: 277.
3. Sebolt J, Scavone S, Pinter C, et al. Pyrazoloacridines: A new class of antitumor agents with selectivity against solid tumors in vitro. Cancer Res 1987; 47: 4299-4304.
4. Sebolt J, Havlick M, Hamelehle K, et al. Activity of the pyrazoloacridines against multidrug-resistant tumor cells. Cancer Chemother Pharmacol 1989; 24: 219-24.
5. Berg S, Blaney S, Adamson P, et al. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol 1998; 16: 181-6.
6. LoRusso P, Foster B, Poplin E, et al. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). Clinical Cancer Res 1995; 1: 1487-93.
7. Rowinsky E, Noe D, Growchow L, et al. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple dosing schedules. J Clin Oncol 1995; 13: 1975-84.
8. Guidelines for Reporting of Adverse Drug Reactions, Bethesda, MD. Division of Cancer Treatment, National Cancer Institute. 1988.
9. LoRusso P, Wozniak AJ, Polin L, et al. Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res 1990; 50: 4900-5.
10. Sebolt J, Leopold W, Hamelehle K, et al. Solid tumor selectivity of the 2-aminoalkyl-5-nitro-pyrazolo[3,4,5-kl]acridines: A novel class of DNA binding antitumor agents (Abstract). Proc Am Assoc Cancer Res 1986; 27: 421.
11. Leopold W, Fry D, Nelson J, et al. In vivo activity and biochemical characterization of substituted [1]benzothiopyrano[4,3,2-cd]indazoles: A novel class of DNA-binding anticancer agents (Abstract). Proc Am Assoc Cancer Res 1985; 26: 253.
12. Nitschke R, Parkhurst J, Harris JSM, et al. Topotecan in pediatric patients with recurrenta nd progressive solid tumors: A Pediatric Oncology Group Phase II Study. J Pediatr Hematol Oncol 1998; 20: 315-8.
13. Harris M, Hurwitz C, Sullivan J, et al. Taxol in pediatric solid tumors: A Pediatric Oncology Group Phase II study. Proc Am Soc Clin Oncol 1999; 18: 2170.